Close Menu

NEW YORK – Cofactor Genomics said Tuesday that it will partner with the University of California, San Diego, to continue to study the utility of its predictive immune modeling technology in personalizing immunotherapy treatment for head and neck cancers.

The company noted that improving therapy selection for this hard-to-treat tumor type has become especially important given the US Food and Drug Administration's recent approval of pembrolizumab (Merk's Keytruda) as a first-line option for recurrent and metastatic, squamous cell head and neck carcinoma.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by
Beckman Coulter

This webinar will discuss a streamlined library preparation method for next-generation sequencing (NGS) that improves quality control testing capability while reducing the total number of steps compared to conventional multiplexed library workflows.

Sponsored by

NTRK fusions are oncogenic drivers in a variety of tumors.

Sponsored by

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Sponsored by

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.